explore -WSS

explore

author：comprehensive 2025-10-01 18:35:19 - browse：7

A display of TVs against an orange background. -- health policy coverage from STAT — Adobe

WASHINGTON — Government regulators may soon decide whether to crack down on distracting visuals in television drug commercials or require subtitles about side effects, a regulation that’s been 13 years in the making.

White House budget experts are reviewing changes to the regulation of broadcast drug advertisements that the Food and Drug Administration proposed in 2010, according to the Office of Management and Budget website. That proposal aimed to make commercials present drug risks in a manner that consumers notice and understand.

Drug ads have long been controversial. Aside from New Zealand, the United States is the only country that allows drug makers to advertise to consumers. Critics of drug ads say they pose consumer safety concerns by bombarding the public with promotions that distract viewers from potential side effects. Drug companies say commercials spark conversations between patients and doctors that promote clinically beneficial prescribing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： With Wegovy coverage, Medicare patients may face high costs

Wikipedia

WSS

Cancer, immunology, HIV research ensnared in fetal tissue politics

Boston hospital trains restaurant workers on naloxone for overdoses

What Kate Middleton's cancer revelation might teach the world

WuXi Biologics execs register to lobby as Congress comes for the company

CVS is willing to dump 10% of its Medicare Advantage members

Chinese researcher claims birth of first gene

focus

explore

hotspot

Medicare details structure of new drug price negotiation program

WuXi Biologics beefs up its lobbying operation

What does generative AI mean for health care? We asked experts

Obesity drug from Roche shows promise in early study

Psychedelics group wrestles with new pharma identity

Yancopoulos of Regeneron works to expand Dupixent success

Medical records are filled with copy

HHS suspends federal funding for EcoHealth Alliance

Medicare details structure of new drug price negotiation program

Bring on the sabbaticals for nurses

focus

Biotech investment managers search for lucrative opportunities

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Readout Newsletter: Illumina, CRISPR, Regeneron

Texas board proposes rules on abortion law emergency exemption

U.K. officials, researchers try to ease path for bespoke genetic treatments

Adam's Take: Intra

knowledge

leisure time

Wikipedia

hotspot